Last update 01 Nov 2024

4-1BB x IL2RA x HPV E7

Last update 01 Nov 2024

Basic Info

Related Targets

4-1BBIL2RAHPV E7

Drugs associated with 4-1BB x IL2RA x HPV E7

RTX-321

Target

4-1BB x HPV E7 x IL2RA

Mechanism

4-1BB agonists [+2]

Active Org.-

Originator Org.

Rubius Therapeutics, Inc.

Active Indication-

Inactive Indication

Advanced cancer [+5]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with 4-1BB x IL2RA x HPV E7

NCT04672980 / TerminatedPhase 1

A Phase 1 Study of RTX-321 for the Treatment of Patients With Advanced Malignancies Associated With Human Papillomavirus-16 Infection

This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16+ cancers.

Start Date08 Apr 2021

Sponsor / Collaborator

Rubius Therapeutics, Inc.

100 Clinical Results associated with 4-1BB x IL2RA x HPV E7

100 Translational Medicine associated with 4-1BB x IL2RA x HPV E7

0 Patents (Medical) associated with 4-1BB x IL2RA x HPV E7

Literatures (Medical) associated with 4-1BB x IL2RA x HPV E7

15 May 2010·Cancer ResearchQ1 · MEDICINE

4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines

Q1 · MEDICINE

Article

Author: Shirwan, Haval ; MacLeod, Kathryn J. ; Elpek, Kutlu G. ; Sharma, Rajesh K. ; Yolcu, Esma S. ; Zhong, Zhenping ; Srivastava, Abhishek K. ; Schabowsky, Rich-Henry ; Miller, Robert W. ; Zhao, Hong ; Madireddi, Shravan

AbstractTherapeutic subunit vaccines based on tumor-associated antigens (TAA) represent an attractive approach for the treatment of cancer. However, poor immunogenicity of TAAs requires potent adjuvants for therapeutic efficacy. We recently proposed the tumor necrosis factor family costimulatory ligands as potential adjuvants for therapeutic vaccines and, hence, generated a soluble form of 4-1BBL chimeric with streptavidin (SA-4-1BBL) that has pleiotropic effects on cells of innate, adaptive, and regulatory immunity. We herein tested whether these effects can translate into effective cancer immunotherapy when SA-4-1BBL was also used as a vehicle to deliver TAAs in vivo to dendritic cells (DCs) constitutively expressing the 4-1BB receptor. SA-4-1BBL was internalized by DCs upon receptor binding and immunization with biotinylated antigens conjugated to SA-4-1BBL resulted in increased antigen uptake and cross-presentation by DCs, leading to the generation of effective T-cell immune responses. Conjugate vaccines containing human papillomavirus 16 E7 oncoprotein or survivin as a self-TAA had potent therapeutic efficacy against TC-1 cervical and 3LL lung carcinoma tumors, respectively. Therapeutic efficacy of the vaccines was associated with increased CD4+ T and CD8+ T-cell effector and memory responses and higher intratumoral CD8+ T effector/CD4+CD25+Foxp3+ T regulatory cell ratio. Thus, potent pleiotropic immune functions of SA-4-1BBL combined with its ability to serve as a vehicle to increase the delivery of antigens to DCs in vivo endow this molecule with the potential to serve as an effective immunomodulatory component of therapeutic vaccines against cancer and chronic infections. Cancer Res; 70(10); 3945–54. ©2010 AACR.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis